Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Konrad Klinghammer

Showing results (1-10 of 45) with videos related to

Pageof 5
Sort By:
Cancer Treatment Reviews|March 18, 2017
Choosing wisely - Preclinical test models in the era of precision medicineKonrad Klinghammer, Wolfgang Walther, Jens Hoffmann
Cancers of the Head & Neck|July 28, 2020
Preclinical models of head and neck squamous cell carcinoma for a basic understanding of cancer biology and its translation into efficient therapiesIngeborg Tinhofer, Diana Braunholz, Konrad Klinghammer
Oncology Research and Treatment|November 28, 2016
Targeted Therapy of Head and Neck CancerDamian T Rieke, Konrad Klinghammer, Ulrich Keilholz
Journal of the American Society for Mass Spectrometry|January 16, 2026
Continuous Flow Paper Spray Ionization Mass Spectrometry for In-Depth Characterization of Anticancer Drugs in Tissues: Addressing Mass Spectral ComplexityPallab Basuri, Konrad Klinghammer, Oliver Klein, et al.
Oncology and Therapy|November 21, 2025
A Podcast Discussion on Medical Treatment in R/M-SCCHN in the Year 2025-Standard and Considerations for an Individualized TreatmentPhilipp Ivanyi, Tabea Fröhlich, Jonas Paul Wiegmann, et al.
Head & Neck|January 15, 2014
PI3K/PTEN/AKT/mTOR polymorphisms: association with clinical outcome in patients with head and neck squamous cell carcinoma receiving cetuximab-docetaxelKatharina Pfisterer, Alberto Fusi, Konrad Klinghammer, et al.
Journal of Perinatal Medicine|June 22, 2012
Developmental delay in hypoxia-induced HO-1 expression predisposes to gut injuryJudith Pietzcker, Christof Kluthea, Konrad Klinghammer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 24, 2009
Association of epidermal growth factor receptor polymorphism, skin toxicity, and outcome in patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatmentKonrad Klinghammer, Maren Knödler, Alexander Schmittel, et al.
Frontiers in Oncology|February 14, 2022
Treatment Stratification in First-Line Recurrent or Metastatic Head and Neck Cancer, on Behalf of the EORTC Young Investigator Head and Neck Cancer GroupKonrad Klinghammer, Luigi Lorini, Daan Nevens, et al.
Frontiers in Oncology|November 25, 2024
Diving into hot topics of salivary gland carcinoma management-an EORTC young and early career investigator surveyLuigi Lorini, Sara Ronchi, Daan Nevens, et al.
Pageof 5

Showing results (1-10 of 45) with videos related to

Sort By:
Pageof 5
Cancer Treatment Reviews|March 18, 2017
Choosing wisely - Preclinical test models in the era of precision medicineKonrad Klinghammer, Wolfgang Walther, Jens Hoffmann
Cancers of the Head & Neck|July 28, 2020
Preclinical models of head and neck squamous cell carcinoma for a basic understanding of cancer biology and its translation into efficient therapiesIngeborg Tinhofer, Diana Braunholz, Konrad Klinghammer
Oncology Research and Treatment|November 28, 2016
Targeted Therapy of Head and Neck CancerDamian T Rieke, Konrad Klinghammer, Ulrich Keilholz
Journal of the American Society for Mass Spectrometry|January 16, 2026
Continuous Flow Paper Spray Ionization Mass Spectrometry for In-Depth Characterization of Anticancer Drugs in Tissues: Addressing Mass Spectral ComplexityPallab Basuri, Konrad Klinghammer, Oliver Klein, et al.
Oncology and Therapy|November 21, 2025
A Podcast Discussion on Medical Treatment in R/M-SCCHN in the Year 2025-Standard and Considerations for an Individualized TreatmentPhilipp Ivanyi, Tabea Fröhlich, Jonas Paul Wiegmann, et al.
Head & Neck|January 15, 2014
PI3K/PTEN/AKT/mTOR polymorphisms: association with clinical outcome in patients with head and neck squamous cell carcinoma receiving cetuximab-docetaxelKatharina Pfisterer, Alberto Fusi, Konrad Klinghammer, et al.
Journal of Perinatal Medicine|June 22, 2012
Developmental delay in hypoxia-induced HO-1 expression predisposes to gut injuryJudith Pietzcker, Christof Kluthea, Konrad Klinghammer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 24, 2009
Association of epidermal growth factor receptor polymorphism, skin toxicity, and outcome in patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatmentKonrad Klinghammer, Maren Knödler, Alexander Schmittel, et al.
Frontiers in Oncology|February 14, 2022
Treatment Stratification in First-Line Recurrent or Metastatic Head and Neck Cancer, on Behalf of the EORTC Young Investigator Head and Neck Cancer GroupKonrad Klinghammer, Luigi Lorini, Daan Nevens, et al.
Frontiers in Oncology|November 25, 2024
Diving into hot topics of salivary gland carcinoma management-an EORTC young and early career investigator surveyLuigi Lorini, Sara Ronchi, Daan Nevens, et al.
Pageof 5